BRAF p.V600E variant increases the growth and spread of cancer cells and, although, in some types of cancer, such as melanoma or non-small cell lung cancer, BRAF inhibitors have clinical activity in the V600E variant, these inhibitors alone have limited activity in BRAF V600E-mutated CRC [182]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.